Data-driven therapeutics company Octant Bio is exploring new frontiers of drug development with $80 million in-pocket and a freshly signed Big Pharma partnership. Octant—a historical instrument used ...

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation ...

Octant Bio set out on a journey to show that the convergence of synthetic biology, chemistry, and computational techniques could lead to new drugs for patients. That destination is still distant, but ...

EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it has expanded its agreement with Octant to further scale their next-generation ...

Octant doubles its initial investment in Zymergen’s Automation Technology to significantly increase the scale and throughput of its drug discovery platform EMERYVILLE, Calif., July 14, 2022 (GLOBE ...